Moreover, neutralizing antibodies against IL-17 predispose individuals to chronic mucocutaneous candidiasis (CMC), commonly seen in AIRE-deficient patients [99,100] and occasionally in individuals undergoing anti-IL-17 biologic therapy for autoimmunity [101]. The gene discussed is IL17A; the disease is Chronic mucocutaneous candidosis.